A Clinical Trial for the Safety and Effect of MRGuided FUS Subthalamotomy for Medication Refractory Parkinson's Disease

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2019

Primary Completion Date

May 31, 2022

Study Completion Date

July 31, 2022

Conditions
Parkinson Disease
Interventions
DEVICE

ExaBlate 4000

The Exablate 4000, an advanced, non-invasive technique for performing ablation of the Thalamus for treating Essential Tremor, received FDA PMA (P150038) approval for unilateral treatment of Essential Tremor in 2016.

Trial Locations (1)

5650871

Osaka University Hospital, Suita

Sponsors

Lead Sponsor

All Listed Sponsors
lead

InSightec

INDUSTRY

NCT04744493 - A Clinical Trial for the Safety and Effect of MRGuided FUS Subthalamotomy for Medication Refractory Parkinson's Disease | Biotech Hunter | Biotech Hunter